Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Starbucks
SBUX
|
+$618M |
| 2 |
Vale
VALE
|
+$332M |
| 3 |
CELG
Celgene Corp
CELG
|
+$309M |
| 4 |
CME Group
CME
|
+$306M |
| 5 |
Amazon
AMZN
|
+$290M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$435M |
| 2 |
Meta Platforms (Facebook)
META
|
+$342M |
| 3 |
Crown Castle
CCI
|
+$244M |
| 4 |
SLB Ltd
SLB
|
+$229M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.17% |
| 2 | Technology | 14.41% |
| 3 | Consumer Discretionary | 10.61% |
| 4 | Financials | 10.51% |
| 5 | Real Estate | 9.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3251
Stagwell
STGW
$2.03B
| $149K | ﹤0.01% |
+66,000
| New | +$181K |
|
|
QNRX
3252
Quoin Pharmaceuticals
QNRX
$8.38M
| $148K | ﹤0.01% |
+1
| New | +$179K |
|
3253
XWELL
XWEL
$8.95M
| $147K | ﹤0.01% |
1,018
+329
| +48% | +$73K |
|
3254
SIFCO Industries
SIF
$170M
| $145K | ﹤0.01% |
52,500
+1,800
| +4% | +$5.74K |
|
|
MJCO
3255
DELISTED
Majesco
MJCO
| $145K | ﹤0.01% |
+20,500
| New | +$152K |
|
|
BVSN
3256
DELISTED
Broadvision Inc Com
BVSN
| $144K | ﹤0.01% |
88,300
-2,200
| -2% | -$3.35K |
|
|
NH
3257
DELISTED
NantHealth, Inc
NH
| $143K | ﹤0.01% |
10,353
+8,020
| +344% | +$92.9K |
|
3258
Daxor
DXR
| $141K | ﹤0.01% |
12,500
+500
| +4% | +$7.46K |
|
3259
Summit Therapeutics
SMMT
$10.6B
| $140K | ﹤0.01% |
76,330
+27,230
| +55% | +$44.7K |
|
|
HIND
3260
Vyome Holdings
HIND
$14.5M
| – | – |
0
| – | – |
|
|
CISN
3261
DELISTED
Cision Ltd. Ordinary Share
CISN
| $139K | ﹤0.01% |
10,100
-412,400
| -98% | -$5.31M |
|
3262
Red Violet
RDVT
$949M
| $138K | ﹤0.01% |
20,500
+10,500
| +105% | +$76.3K |
|
|
SKYS
3263
DELISTED
Sky Solar Holdings, Ltd.
SKYS
| $138K | ﹤0.01% |
73,492
+56,852
| +342% | +$101K |
|
3264
NextDecade
NEXT
$1.75B
| $137K | ﹤0.01% |
24,900
+13,900
| +126% | +$58K |
|
|
GPOR
3265
DELISTED
Gulfport Energy Corp.
GPOR
| $136K | ﹤0.01% |
16,968
-218,832
| -93% | -$1.74M |
|
3266
Veru
VERU
$35.5M
| $135K | ﹤0.01% |
9,261
+3,031
| +49% | +$43.5K |
|
3267
Cellectar Biosciences
CLRB
$20.5M
| $133K | ﹤0.01% |
189
-1
| -0.5% | -$609 |
|
|
HYGS
3268
DELISTED
Hydrogenics Corp
HYGS
| $133K | ﹤0.01% |
16,750
+2,270
| +16% | +$16.6K |
|
|
PBBI
3269
DELISTED
PB Bancorp, Inc. Common Stock
PBBI
| $132K | ﹤0.01% |
+11,500
| New | +$128K |
|
|
UQM
3270
DELISTED
UQM Technologies, Inc.
UQM
| $132K | ﹤0.01% |
+79,699
| New | +$121K |
|
|
SLNO
3271
DELISTED
Soleno Therapeutics
SLNO
| $131K | ﹤0.01% |
+4,242
| New | +$113K |
|
3272
Atlantic American Corp
AAME
$31.6M
| $129K | ﹤0.01% |
50,600
+800
| +2% | +$2.14K |
|
3273
Caledonia Mining Corp
CMCL
$358M
| $129K | ﹤0.01% |
+21,400
| New | +$125K |
|
|
NOVN
3274
DELISTED
Novan, Inc. Common Stock
NOVN
| $129K | ﹤0.01% |
13,529
-3,575
| -21% | -$45.2K |
|
3275
Moleculin Biotech
MBRX
$2.83M
| $127K | ﹤0.01% |
70
+52
| +289% | +$155K |
|
Similar funds
Renaissance Technologies's Q1 2019 Portfolio in Review
As of Q1 2019, Renaissance Technologies held 3,883 positions worth $110B, up 20% from $91.3B the previous quarter. Its ten largest holdings account for 8.7% of the portfolio.
Renaissance Technologies deployed $7.09B of net new capital in Q1 2019, opening 532 new positions and adding to 1,751 existing holdings. Its largest new stake was Amazon: 3,483,100 shares worth $310M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Meta Platforms (Facebook), an estimated $342M trimmed.
- Renaissance Technologies's largest Q1 2019 buy was Amazon: 3,483,100 shares worth $310M.
- Renaissance Technologies added most to Starbucks in Q1 2019, an estimated $618M increase.
- Renaissance Technologies's biggest Q1 2019 reduction was Meta Platforms (Facebook), cutting an estimated $342M.
- Renaissance Technologies fully exited Apple in Q1 2019, selling an estimated $435M.
- Renaissance Technologies's ten largest holdings make up 8.7% of its $110B portfolio in Q1 2019.
- Renaissance Technologies opened 532 new positions and closed 465 in Q1 2019.
- Renaissance Technologies's portfolio value rose 20% quarter-over-quarter to $110B.
Based on Renaissance Technologies's 13F filing for Q1 2019, filed 14 May 2019.